References
Key articles
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].Full text
Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.Full text Abstract
Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).Full text Abstract
World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Full text
Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.Full text Abstract
Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93. Abstract
Reference articles
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
2. Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ. 2008 Jun 17;178(13):1679-82.Full text Abstract
3. Panenka WJ, Procyshyn RM, Lecomte T, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013 May 1;129(3):167-79. Abstract
4. Moszczynska A. Neurobiology and clinical manifestations of methamphetamine neurotoxicity. Psychiatr Times. 2016 Sep;33(9):16-8.Full text Abstract
5. National Institute on Drug Abuse. Methamphetamine research report: what is methamphetamine? Oct 2019 [internet publication].Full text
6. Paulus MP, Stewart JL. Neurobiology, clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020 Sep 1;77(9):959-66.Full text Abstract
7. United Nations Office on Drugs and Crime. World drug report 2022. Jun 2022 [internet publication].Full text
8. Stoneberg DM, Shukla RK, Magness MB. Global methamphetamine trends: an evolving problem. Int Crim Just Rev. 2017;28(2):136-61.Full text
9. European Monitoring Centre for Drugs and Drug Addiction. EU drug market: methamphetamine. 2022 [internet publication].Full text
10. Substance Abuse and Mental Health Services Administration (SAMHSA). 2021 National Survey of Drug Use and Health (NSDUH) releases. 2021 [internet publication].Full text
11. Chen T, Spiller HA, Badeti J, et al. Methamphetamine exposures reported to United States poison control centers, 2000-2019. Clin Toxicol (Phila). 2021 Aug;59(8):705-14. Abstract
12. Monitoring the Future. Methamphetamine: trends in last 12 months prevalence of use in 8th, 10th, and 12th grade. 2023 [internet publication].Full text
13. American Society of Addiction Medicine/American Academy of Addiction Psychiatry. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun;18(1S):1-56.Full text
14. Centers for Disease Control and Prevention. CDC WONDERSearch: about underlying cause of death, 1999-2020. 2023 [internet publication].Full text
15. Hedegaard H, Bastian BA, Trinidad JP, et al. Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. Natl Vital Stat Rep. 2018 Dec;67(9):1-14.Full text Abstract
16. Winkelman TNA, Admon LK, Jennings L, et al. Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States. JAMA Netw Open. 2018 Oct 5;1(6):e183758.Full text Abstract
17. Hedegaard H, Bastian BA, Trinidad JP, et al. Regional differences in the drugs most frequently involved in drug overdose deaths: United States, 2017. Natl Vital Stat Rep. 2019 Oct;68(12):1-16.Full text Abstract
18. Kariisa M, Scholl L, Wilson N, et al. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):388-95.Full text Abstract
19. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020 Apr;94(4):1085-133.Full text Abstract
20. Daniulaityte R, Silverstein SM, Crawford TN, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. city. Subst Use Misuse. 2020;55(11):1781-9.Full text Abstract
21. Glick SN, Klein KS, Tinsley J, et al. Increasing heroin-methamphetamine (goofball) use and related morbidity among Seattle area people who inject drugs. Am J Addict. 2021 Mar;30(2):183-91.Full text Abstract
22. Glick SN, Burt R, Kummer K, et al. Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. Drug Alcohol Depend. 2018 Jan 1;182:86-92.Full text Abstract
23. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment for stimulant use disorders: updated 2021. Treatment Improvement Protocol (TIP) series, no. 33. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 1999 (updated 2021).Full text Abstract
24. Centers for Disease Control and Prevention. Annual surveillance report of drug-related risks and outcomes: United States, 2019. Nov 2019 [internet publication].Full text
25. Pro G, Hayes C, Montgomery BEE, et al. Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019. Drug Alcohol Depend. 2022 Aug 1;237:109535. Abstract
26. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017. 2017 [internet publication].Full text
27. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011 Apr 30;186(2-3):356-61.Full text Abstract
28. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis. 2014 Jun;29(2):351-7. Abstract
29. Zhou Y, Hu Y, Wang Q, et al. Association between white matter microstructure and cognitive function in patients with methamphetamine use disorder. Hum Brain Mapp. 2023 Feb 1;44(2):304-14.Full text Abstract
30. Hart CL, Marvin CB, Silver R, et al. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012 Feb;37(3):586-608.Full text Abstract
31. Basterfield C, Hester R, Bowden SC. A meta-analysis of the relationship between abstinence and neuropsychological functioning in methamphetamine use disorder. Neuropsychology. 2019 Jul;33(5):739-53. Abstract
32. Sung YH, Cho SC, Hwang J, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007 Apr 17;88(1):28-35. Abstract
33. Hall MG, Alhassoon OM, Stern MJ, et al. Gray matter abnormalities in cocaine versus methamphetamine-dependent patients: a neuroimaging meta-analysis. Am J Drug Alcohol Abuse. 2015;41(4):290-9. Abstract
34. Lyoo IK, Yoon S, Kim TS, et al. Predisposition to and effects of methamphetamine use on the adolescent brain. Mol Psychiatry. 2015 Dec;20(12):1516-24.Full text Abstract
35. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001 Aug;36(1):1-22. Abstract
36. Whitesell M, Bachand A, Peel J, et al. Familial, social, and individual factors contributing to risk for adolescent substance use. J Addict. 2013 Mar 20;2013:579310.Full text Abstract
37. Kilpatrick DG, Acierno R, Saunders B, et al. Risk factors for adolescent substance abuse and dependence: data from a national sample. J Consult Clin Psychol. 2000 Feb;68(1):19-30. Abstract
38. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychol Bull. 1992 Jul;112(1):64-105. Abstract
39. Chen Y, Zhang J, Sun Y. The relationship between childhood abuse and depression in a sample of Chinese people who use methamphetamine. Int J Clin Health Psychol. 2019 Sep;19(3):181-18.Full text Abstract
40. Simpson JL, Grant KM, Daly PM, et al. Psychological burden and gender differences in methamphetamine-dependent individuals in treatment. J Psychoactive Drugs. 2016 Sep-Oct;48(4):261-9. Abstract
41. Svingen L, Dykstra RE, Simpson JL, et al. Associations between family history of substance use, childhood trauma, and age of first drug use in persons with methamphetamine dependence. J Addict Med. 2016 Jul-Aug;10(4):269-73. Abstract
42. Hendrickson RG, Horowitz BZ, Norton RL. "Parachuting" meth: a novel delivery method for methamphetamine and delayed-onset toxicity from "body stuffing". Clin Toxicol (Phila). 2006;44(4):379-82. Abstract
43. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 Nov 21;264(19):2511-8. Abstract
44. O'Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev. 2011 Feb;31(1):104-12. Abstract
45. Shadur JM, Lejuez CW. Adolescent substance use and comorbid psychopathology: emotion regulation deficits as a transdiagnostic risk factor. Curr Addict Rep. 2015 Dec 1;2(4):354-63.Full text Abstract
46. McKetin R, Kothe A, Baker AL, et al. Predicting abstinence from methamphetamine use after residential rehabilitation: findings from the Methamphetamine Treatment Evaluation Study. Drug Alcohol Rev. 2018 Jan;37(1):70-8. Abstract
47. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, et al; Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 Apr;197(4):225-31.Full text Abstract
48. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults: US Preventive Services Task Force recommendation statement. JAMA. 2020 May 26;323(20):2060-6.Full text Abstract
49. Mullen JM, Richards JR, Crawford AT. Amphetamine related psychiatric disorders. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.Full text Abstract
50. Brecht ML, Herbeck D. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend. 2014 Jun 1;139:18-25.Full text Abstract
51. Yimsaard P, Maes MM, Verachai V, et al. Pattern of methamphetamine use and the time lag to methamphetamine dependence. J Addict Med. 2018 Mar/Apr;12(2):92-8.Full text Abstract
52. Chen LY, Strain EC, Alexandre PK, et al. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014 May;39(5):829-36.Full text Abstract
53. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018 Dec 1;193:14-20. Abstract
54. Lineberry TW, Bostwick JM. Methamphetamine abuse: a perfect storm of complications. Mayo Clin Proc. 2006 Jan;81(1):77-84. Abstract
55. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006 Aug;26(8):1148-56. Abstract
56. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010 Aug;48(7):675-94. Abstract
57. Department of Health and Social Care (UK). Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].Full text
58. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014 Dec;28(12):1115-26.Full text Abstract
59. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb;120(2):165-71. Abstract
60. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec;130(6):1657-63. Abstract
61. Goodchild JH, Donaldson M. Methamphetamine abuse and dentistry: a review of the literature and presentation of a clinical case. Quintessence Int. 2007 Jul-Aug;38(7):583-90. Abstract
62. Hargraves D, White C, Frederick R, et al. Implementing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38:31.Full text Abstract
63. American College of Surgeons. Best practices guidelines: screening and intervention for mental health disorders and substance use and misuse in the acute trauma patient. Dec 2022 [internet publication].Full text
64. US Preventive Services Task Force. Final recommendation statement. Unhealthy drug use: screening. Jun 2020 [internet publication].Full text
65. Levy SJ, Williams JF; Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016 Jul;138(1):e20161211.Full text Abstract
66. National Institute for Health and Care Excellence. Postnatal care. Apr 2021 [internet publication].Full text
67. McKay JR. Impact of continuing care on recovery from substance use disorder. Alcohol Res. 2021 Jan 21;41(1):01.Full text Abstract
68. Iturralde E, Weisner CM, Adams SR, et al. Patterns of health care use 5 years after an intervention linking patients in addiction treatment with a primary care practitioner. JAMA Netw Open. 2022 Nov 1;5(11):e2241338.Full text Abstract
69. Minozzi S, Saulle R, Amato L, et al. Psychosocial interventions for stimulant use disorder. Cochrane Database Syst Rev. 2024 Feb 15;2(2):CD011866.Full text Abstract
70. US Department of Veterans Affairs. VA/DoD clinical practice guidelines: management of substance use disorder (SUD). Aug 2021 [internet publication].Full text
71. United Nations Office on Drugs and Crime. UNODC treatment of stimulant use disorders: current practices and promising perspectives. May 2019 [internet publication].Full text
72. Shoptaw S, Reback CJ. Associations between methamphetamine use and HIV among men who have sex with men: a model for guiding public policy. J Urban Health. 2006 Nov;83(6):1151-7.Full text Abstract
73. Sherman SG, Sutcliffe C, Srirojn B, et al. Evaluation of a peer network intervention trial among young methamphetamine users in Chiang Mai, Thailand. Soc Sci Med. 2009 Jan;68(1):69-79.Full text Abstract
74. McGovern R, Newham JJ, Addison MT, et al. Effectiveness of psychosocial interventions for reducing parental substance misuse. Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD012823.Full text Abstract
75. Stuart AM, Baker AL, Denham AMJ, et al. Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: a systematic review. J Subst Abuse Treat. 2020 Feb;109:61-79.Full text Abstract
76. De Crescenzo F, Ciabattini M, D'Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: a systematic review and network meta-analysis. PLoS Med. 2018 Dec;15(12):e1002715.Full text Abstract
77. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006 Feb;101(2):267-74. Abstract
78. Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Nov 1;216:108307. Abstract
79. Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS One. 2020;15(6):e0234809.Full text Abstract
80. Rawson R, Gonzales R, Brethen P. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002 Sep;23(2):145-50. Abstract
81. Roll JM, Petry NM, Stitzer ML, et al. Contingency for the treatment of methamphetamine use disorder. Am J Psychiatry. 2006 Nov;163(11):1993-9. Abstract
82. Bentzley BS, Han SS, Neuner S, et al. Comparison of treatments for cocaine use disorder among adults: a systematic review and meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e218049.Full text Abstract
83. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994 Jul;51(7):568-76. Abstract
84. Rawson RA, Huber A, McCann M, et al. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry. 2002 Sep;59(9):817-24.Full text Abstract
85. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006 Nov;101(11):1546-60. Abstract
86. Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010 Aug 7;376(9739):458-74. Abstract
87. McPherson SM, Burduli E, Smith CL, et al. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018;9:43-57.Full text Abstract
88. Kurti AN, Davis DR, Redner R, et al. A review of the literature on remote monitoring technology in incentive-based interventions for health-related behavior change. Transl Issues Psychol Sci. 2016 Jun;2(2):128-52.Full text Abstract
89. Harada T, Tsutomi H, Mori R, et al. Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders. Cochrane Database Syst Rev. 2018 Dec 22;(12):CD011315.Full text Abstract
90. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008 Feb;165(2):179-87.Full text Abstract
91. Maude-Griffin PM, Hohenstein JM, Humfleet GL, et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998 Oct;66(5):832-7. Abstract
92. Rohsenow DJ, Monti PM, Martin RA, et al. Brief coping skills treatment for cocaine abuse: 12-month substance use outcomes. J Consult Clin Psychol. 2000 Jun;68(3):515-20. Abstract
93. Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994 Mar;51(3):177-87. Abstract
94. Schwenker R, Dietrich CE, Hirpa S, et al. Motivational interviewing for substance use reduction. Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD008063. Abstract
95. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005 May 9;78(2):125-34. Abstract
96. AshaRani PV, Hombali A, Seow E, et al. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020 Jul 1;212:108060.Full text Abstract
97. Amiri Z, Mirzaee B, Sabet M. Evaluating the efficacy of regulated 12-session Matrix Model in reducing susceptibility in methamphetamine-dependent individuals. Int J Med Res Health Sci. 2016;5(2):77-85.Full text
98. De Giorgi R, Cassar C, Loreto D'alò G, et al. Psychosocial interventions in stimulant use disorders: a systematic review and qualitative synthesis of randomized controlled trials. Riv Psichiatr. 2018 Sep-Oct;53(5):233-55.Full text Abstract
99. McLellan AT, Hagan TA, Meyers K, et al. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment. J Addict Dis. 1997;16(2):57-84. Abstract
100. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009 May;22(3):263-8.Full text Abstract
101. Wouldes T, LaGasse L, Sheridan J, et al. Maternal methamphetamine use during pregnancy and child outcome: what do we know? N Z Med J. 2004 Nov 26;117(1206):U1180. Abstract
102. Eze N, Smith LM, LaGasse LL, et al. School-aged outcomes following prenatal methamphetamine exposure: 7.5-year follow-up from the Infant Development, Environment, and Lifestyle Study. J Pediatr. 2016 Mar;170:34-8.e1.Full text Abstract
103. World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Full text
104. Washio Y, Atreyapurapu S, Hayashi Y, et al. Systematic review on use of health incentives in U.S. to change maternal health behavior. Prev Med. 2021 Apr;145:106442. Abstract
105. Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020 Apr;34(4):337-65.Full text Abstract
106. Soares E, Pereira FC. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups. Expert Opin Pharmacother. 2019 Dec;20(18):2273-93. Abstract
107. Lee NK, Jenner L, Harney A, et al. Pharmacotherapy for amphetamine dependence: a systematic review. Drug Alcohol Depend. 2018 Oct 1;191:309-37. Abstract
108. Chan B, Freeman M, Kondo K, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder - a systematic review and meta-analysis. Addiction. 2019 Dec;114(12):2122-36. Abstract
109. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33. Abstract
110. Longo M, Wickes W, Smout M, et al. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010 Jan;105(1):146-54. Abstract
111. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489-500.Full text Abstract
112. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Jul;108(7):1279-86. Abstract
113. Solhi H, Jamilian HR, Kazemifar AM, et al. Methylphenidate vs. resperidone in treatment of methamphetamine dependence: a clinical trial. Saudi Pharm J. 2014 Jul;22(3):191-4.Full text Abstract
114. Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015 Sep;40(10):2347-56.Full text Abstract
115. Comer SD, Mogali S, Saccone PA, et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013 Nov;38(12):2427-38.Full text Abstract
116. Stoops WW, Rush CR. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Rev Clin Pharmacol. 2014 May;7(3):363-74.Full text Abstract
117. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021 Jan 14;384(2):140-53.Full text Abstract
118. De La Garza R 2nd, Newton TF, Haile CN, et al. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141-6. Abstract
119. Chang CH, Liou MF, Liu CY, et al. Efficacy of repetitive transcranial magnetic stimulation in patients with methamphetamine use disorder: a systematic review and meta-analysis of double-blind randomized controlled trials. Front Psychiatry. 2022 May 27;13:904252.Full text Abstract
120. Makani R, Pradhan B, Shah U, et al. Role of repetitive transcranial magnetic stimulation (rTMS) in treatment of addiction and related disorders: a systematic review. Curr Drug Abuse Rev. 2017;10(1):31-43. Abstract
121. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct;108(1):76-85. Abstract
122. Collins KC, Schlosburg JE, Bremer PT, et al. Methamphetamine vaccines: improvement through hapten design. J Med Chem. 2016 Apr 28;59(8):3878-85.Full text Abstract
123. Farahzadi MH, Moazen-Zadeh E, Razaghi E, et al. Riluzole for treatment of men with methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2019 Mar;33(3):305-15. Abstract
124. Goldberg SB, Pace B, Griskaitis M, et al. Mindfulness-based interventions for substance use disorders. Cochrane Database Syst Rev. 2021 Oct 20;(10):CD011723.Full text Abstract
125. Maneesang W, Hengpraprom S, Kalayasiri R. Effectiveness of mindfulness-based therapy and counseling programs (MBTC) on relapses to methamphetamine dependence at a substance dependency treatment center. Psychiatry Res. 2022 Nov;317:114886. Abstract
126. Rostami R, Dehghani-Arani F. Neurofeedback training as a new method in treatment of crystal methamphetamine dependent patients: a preliminary study. Appl Psychophysiol Biofeedback. 2015 Sep;40(3):151-61. Abstract
127. Crowley R, Kirschner N, Dunn AS, et al. Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: an American College of Physicians position paper. Ann Intern Med. 2017 May 16;166(10):733-6.Full text Abstract
128. Calabria BD, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav. 2010 Aug;35(8):741-9. Abstract
129. Turnipseed SD, Richards JR, Kirk D, et al. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med. 2003 May;24(4):369-73. Abstract
130. Mortelmans LJM, Bogaerts PJM, Hellemans S, et al. Spontaneous pneumomediastinum and myocarditis following ecstasy use: a case report. Eur J Emerg Med. 2005 Feb;12(1):36-8. Abstract
131. Dickson SD, Thomas IC, Bhatia HS, et al. Methamphetamine-associated heart failure hospitalizations across the United States: geographic and social disparities. J Am Heart Assoc. 2021 Aug 17;10(16):e018370.Full text Abstract
132. Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. J Forensic Sci. 1999 Jan;44(1):23-6. Abstract
133. Rejali D, Glen P, Odom N. Pneumomediastinum following ecstasy (methylenedioxymethamphetamine, MDMA) ingestion in two people at the same "rave". J Laryngol Otol. 2002 Jan;116(1):75-6. Abstract
134. National Toxicology Program. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON. 2005 Jul;(16):i-III-1.Full text Abstract
135. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009 Aug;17(4):291-4. Abstract
136. Silber BY, Croft RJ, Papafotiou K, et al. The effects of d-amphetamine and methamphetamine on attention and psychomotor performance. Psychopharmacology (Berl). 2006 Aug;187(2):154-69. Abstract
137. Sheridan J, Bennett S, Coggan C, et al. Injury with methamphetamine use: a review of the literature. Harm Reduct J. 2006 Mar 29;3:14.Full text Abstract
138. Fischer B, Haydon E, Rehm J, et al. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach - the case study of Canada. J Urban Health. 2004 Sep;81(3):428-47.Full text Abstract
139. Centers for Disease Control and Prevention. Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2024. Nov 2023 [internet publication].Full text
140. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021 [internet publication].Full text
Use of this content is subject to our disclaimer